From Follower to Hub: Vietnam’s Bold Clinical Trial Bet to Upgrade Healthcare Economy

The push is also happening as healthcare demand expands and becomes more complex. A Vietnam healthcare market study values the sector at USD 11.85 billion in 2025, rising to USD 13.95 billion in 2026 and USD 22.93 billion by 2032, at a projected 8.64% CAGR for 2026–2032. The same source notes Vietnam’s healthcare infrastructure includes 1,718 hospitals and over 350,000 beds. In this context, clinical trials can act as a capability upgrade. Trial protocols tend to require tighter diagnostics, consistent monitoring, and standardized documentation, which can lift baseline service quality across facilities that participate.

Why Vietnam’s Disease Mix and City Hubs Matter for Trials

Vietnam’s disease burden strengthens the logic for building deeper research capacity. According to one Vietnam healthcare market source, about 25% of patients in Vietnam’s healthcare system in 2026 were affected by cardiovascular diseases, and cancer impacted approximately 35% of the patient population in 2026. Another report states NCDs accounted for 84% of total deaths in Vietnam in 2024, up from approximately 74% in 2022, citing an official Deputy Minister of Health. Within that NCD share, cardiovascular disease leads at ~20.5% and cancer at ~13.3%, with chronic respiratory disease ~4% and diabetes ~3.9%. These realities can translate into clear priorities for sponsors seeking patient access aligned to high-burden conditions.

Execution, however, is still shaped by where capacity concentrates. Reports describe Hanoi and Ho Chi Minh City as dominant hubs for clinical research, supported by high concentrations of hospitals, research institutions, pharmaceutical companies, and international clinical laboratories. That clustering can accelerate study start-up and monitoring quality in major cities, but it can also widen the gap with peripheral provinces. One Vietnam healthcare report flags that workforce ratios lag regional peers and that physician-to-population ratios are suboptimal in specialist disciplines such as oncology, cardiology, and imaging. It adds that limited training pipeline capacity contributes to uneven specialist availability between Hanoi and peripheral provinces, which can constrain adoption of advanced services and burden existing hospital staff.

Vietnam’s next step is to turn market growth into durable operating excellence. The clinical trials market estimate highlights a shift toward precision medicine, describing more tailored trials targeting specific patient populations based on genetic and environmental factors. At the same time, broader Asia-Pacific context shows the operational barriers Vietnam must navigate as it scales. One Asia-Pacific clinical trials report points to compliance complexities from misalignment between national and international ethical and legal standards, and it also cites limited availability of world-class infrastructure and trained professionals in emerging economies as a constraint. As Vietnam works to climb the value chain, success will depend on pairing market expansion with stronger specialist capacity, consistent standards, and practical partnerships that keep studies running smoothly.